Xencor, CardioDx set IPO ranges

Antibody company Xencor Inc. (Monrovia, Calif.) and diagnostic company CardioDx Inc. (Palo Alto, Calif.) amended their IPOs on Monday and plan to sell 5 million shares at $14-$16. At the $15 midpoint, the companies would each raise $75 million. Xencor would be valued at $325.4 million at the price; CardioDx would be valued at $256.5 million. The companies initially proposed IPOs last month, with Xencor seeking up to $69 million and CardioDx seeking up to $86.3 million.

Credit Suisse; Leerink; and Wedbush PacGrow are underwriters for Xencor's IPO. BofA Merrill Lynch; Jefferies; Piper Jaffray; and William Blair are underwriters for CardioDx's offering. ...